Just less than a month until the World Orphan Drug Congress in Boston! We are delighted to announce that IRDiRC is a proud partner and exhibitor at the World Orphan […]
Read More
The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to […]
Read More
IRDiRC Functional Analysis Task Force recently convened for a dynamic 1.5-day workshop in Paris!?? Members of the task force from all over the world came together and discussed methodologies and […]
Read More
A roundtable of EU and national policymakers, industry experts and patients will gather together to discuss the best approach to define unmet medical needs and Belgium’s multi-criteria approach. Around 36 […]
Read MoreThe latest IRDiRC paper, “Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community” has been published in Frontiers in Medicine. The paper is available here. This open-access […]
Read More
Have a look at the latest video from the IRDiRC Consortium Assembly Meeting hosted on 3-4 October in Montréal (Canada) and dive into insightful snippets from different committees discussions! IRDiRC […]
Read More
On December 14, CDER and Duke-Margolis will host a jointly sponsored virtual public meeting on advancing the development of therapeutics through rare disease patient community engagement. The purpose of this […]
Read More
IRDiRC proudly announces the publication of the manuscript “Targeting shared molecular etiologies to accelerate drug development for rare diseases“ online, today. The manuscript is published in the EMBO Molecular Medicine […]
Read More
The International Rare Diseases Research Consortium (IRDiRC) announces new leadership changes in its Funders Constituent Committee (FCC). Dr. Adam Hartman (Program Director at the National Institute of Neurological Disorders and […]
Read More
The Therapies Scientific Committee (TSC) would like to broaden the committee membership, to represent the worldwide rare disease therapies community in its full width, from early innovation towards regulatory approval […]
Read More